{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T14:34:18Z","timestamp":1787236458478,"version":"build-2736575974"},"reference-count":29,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T00:00:00Z","timestamp":1752796800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007880","name":"Johns Hopkins University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007880","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012665","name":"Institute for Clinical Evaluative Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000226","name":"Ontario Ministry of Health and Long-Term Care","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000226","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011627","name":"Industrial Research and Consultancy Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011627","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinical-breast-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Breast Cancer"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.clbc.2025.07.013","type":"journal-article","created":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T16:57:25Z","timestamp":1752857845000},"page":"213-220","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Appropriate Treatment for Stage 1 and 2 Her2-Positive and Triple-Negative Breast Cancer by Immigration Status in Ontario, Canada"],"prefix":"10.1016","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9219-9069","authenticated-orcid":false,"given":"Omolara","family":"Fatiregun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rinku","family":"Sutradhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sho","family":"Podolsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Eisen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence","family":"Paszat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eileen","family":"Rakovitch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.clbc.2025.07.013_bib0001","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1002\/ijc.33588","article-title":"Cancer statistics for the year 2020: an overview","volume":"149","author":"Ferlay","year":"2021","journal-title":"Int J Cancer"},{"issue":"8","key":"10.1016\/j.clbc.2025.07.013_bib0002","first-page":"1","article-title":"How many etiological subtypes of breast cancer: two, three, four, or more?","volume":"106","author":"Anderson","year":"2014","journal-title":"JNCI J Natl Ca Inst"},{"issue":"18","key":"10.1016\/j.clbc.2025.07.013_bib0003","doi-asserted-by":"crossref","first-page":"6456","DOI":"10.1002\/cam4.4158","article-title":"Relationship of established risk factors with breast cancer subtypes","volume":"10","author":"McCarthy","year":"2021","journal-title":"Cancer Med"},{"key":"10.1016\/j.clbc.2025.07.013_bib0004","first-page":"552","article-title":"NCCN guidelines updates: breast cancer","volume":"17","author":"Telli","year":"2019","journal-title":"J Natl Compr Canc Netw"},{"issue":"5","key":"10.1016\/j.clbc.2025.07.013_bib0005","doi-asserted-by":"crossref","first-page":"484","DOI":"10.6004\/jnccn.2021.0023","article-title":"NCCN Guidelines\u00ae insights: breast Cancer, version 4.2021","volume":"19","author":"Gradishar","year":"2021","journal-title":"J Natl Compreh Ca Netw"},{"issue":"6","key":"10.1016\/j.clbc.2025.07.013_bib0006","doi-asserted-by":"crossref","first-page":"691","DOI":"10.6004\/jnccn.2022.0030","article-title":"Breast Cancer, Version 3.2022, NCCN clinical practice guidelines in oncology","volume":"20","author":"Gradishar","year":"2022","journal-title":"J Natl Comprehen Ca Netw"},{"issue":"6","key":"10.1016\/j.clbc.2025.07.013_bib0007","doi-asserted-by":"crossref","first-page":"594","DOI":"10.6004\/jnccn.2023.0031","article-title":"NCCN Guidelines\u00ae insights: breast Cancer, version 4.2023","volume":"21","author":"Gradishar","year":"2023","journal-title":"J Natl Compreh Ca Netw"},{"issue":"6","key":"10.1016\/j.clbc.2025.07.013_bib0008","first-page":"1","article-title":"Reducing health disparities: a priority for Canada (Preface)","volume":"174","author":"Beiser","year":"2005","journal-title":"Can J Public Health"},{"key":"10.1016\/j.clbc.2025.07.013_bib0009","doi-asserted-by":"crossref","first-page":"e602","DOI":"10.1200\/JOP.2016.019497","article-title":"Impact of immigration status on cancer outcomes in Ontario, Canada original contribution CARE DELIVERY original contribution CARE DELIVERY Impact of immigration status on cancer outcomes in Ontario, Canada","volume":"13","author":"Cheung","year":"2016","journal-title":"J Oncol Pract"},{"issue":"SUPPL. 3","key":"10.1016\/j.clbc.2025.07.013_bib0010","doi-asserted-by":"crossref","first-page":"S151","DOI":"10.1016\/S0959-8049(16)30445-2","article-title":"The impact of immigration status and ethnicity and cancer outcomes in Ontario, Canada","volume":"51","author":"Singh","year":"2015","journal-title":"Eur J Ca"},{"issue":"1","key":"10.1016\/j.clbc.2025.07.013_bib0011","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1007\/s10903-021-01262-z","article-title":"Identifying barriers to healthcare access for new immigrants: a qualitative study in Regina, Saskatchewan, Canada","volume":"24","author":"Pandey","year":"2022","journal-title":"J Immigr Minor Health"},{"issue":"2","key":"10.1016\/j.clbc.2025.07.013_bib0012","doi-asserted-by":"crossref","first-page":"169","DOI":"10.17269\/s41997-019-00270-9","article-title":"Neighbourhood-level marginalization and avoidable mortality in Ontario, Canada: a population-based study","volume":"111","author":"Zygmunt","year":"2020","journal-title":"Cndn J Public Health"},{"key":"10.1016\/j.clbc.2025.07.013_bib0013","unstructured":"Ontario Health (Cancer Care Ontario; Ontario). Less Material Resources Associated with Higher Cancer Incidence. 2022 [cited 2025 May 8]."},{"issue":"2","key":"10.1016\/j.clbc.2025.07.013_bib0014","doi-asserted-by":"crossref","first-page":"260","DOI":"10.17269\/s41997-021-00552-1","article-title":"The 2011 and 2016 iterations of the Ontario Marginalization Index: updates, consistency and a cross-sectional study of health outcome associations","volume":"113","author":"van Ingen","year":"2022","journal-title":"Cndn J Public Health"},{"issue":"1","key":"10.1016\/j.clbc.2025.07.013_bib0015","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s12913-016-1303-z","article-title":"Factors related to breast cancer detection mode and time to diagnosis in Alberta, Canada: a population-based retrospective cohort study","volume":"16","author":"Yuan","year":"2016","journal-title":"BMC Health Serv Res"},{"issue":"4","key":"10.1016\/j.clbc.2025.07.013_bib0016","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.3390\/curroncol29040213","article-title":"Clinical utility of multigene profiling assays in early-stage invasive breast cancer: an Ontario Health (Cancer Care Ontario) Clinical practice guideline","volume":"29","author":"Blanchette","year":"2022","journal-title":"Curr Oncol"},{"issue":"27","key":"10.1016\/j.clbc.2025.07.013_bib0017","doi-asserted-by":"crossref","first-page":"3056","DOI":"10.1200\/JCO.21.00934","article-title":"Management of the axilla in early-stage breast cancer: ontario Health (Cancer Care Ontario) and ASCO guideline","volume":"39","author":"Brackstone","year":"2021","journal-title":"J Clin Oncol"},{"issue":"16_suppl","key":"10.1016\/j.clbc.2025.07.013_bib0018","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1200\/JCO.2022.40.16_suppl.e12511","article-title":"Are we overtreating stage I triple negative breast cancer in Ontario? A population-based study using the ICES database","volume":"40","author":"Shum","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clbc.2025.07.013_bib0019","doi-asserted-by":"crossref","first-page":"S114","DOI":"10.3747\/co.22.2322","article-title":"Systemic targeted therapy for HER2-positive early female breast cancer: a systematic review of the evidence for the 2014 cancer care Ontario systemic therapy guideline","volume":"22","author":"Mates","year":"2015","journal-title":"Curr Oncol"},{"issue":"7","key":"10.1016\/j.clbc.2025.07.013_bib0020","doi-asserted-by":"crossref","first-page":"4518","DOI":"10.1245\/s10434-024-15250-8","article-title":"Immigration status and breast cancer surgery quality of care metrics: a population-level analysis","volume":"31","author":"Parvez","year":"2024","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"10.1016\/j.clbc.2025.07.013_bib0021","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10549-022-06522-6","article-title":"A Canadian national guideline on the neoadjuvant treatment of invasive breast cancer, including patient assessment, systemic therapy, and local management principles","volume":"193","author":"Gandhi","year":"2022","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"10.1016\/j.clbc.2025.07.013_bib0022","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s10549-021-06424-z","article-title":"Evaluating anthracycline\u2009+\u2009taxane versus taxane-based chemotherapy in older women with node-negative triple-negative breast cancer: a SEER-Medicare study","volume":"191","author":"Schreiber","year":"2022","journal-title":"Breast Cancer Res Treat"},{"issue":"6","key":"10.1016\/j.clbc.2025.07.013_bib0023","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.3390\/cancers15061917","article-title":"What is known about breast cancer in young women?","volume":"15","author":"Zhu","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"12","key":"10.1016\/j.clbc.2025.07.013_bib0024","doi-asserted-by":"crossref","first-page":"5690","DOI":"10.1177\/00031348231173993","article-title":"Systemic therapy in elderly patients with Her2\/neu-positive breast cancer: a SEER database study","volume":"89","author":"Wilbers","year":"2023","journal-title":"Am Surg"},{"key":"10.1016\/j.clbc.2025.07.013_bib0025","unstructured":"Health services research. Health Services Research _ Canadian Cancer Society, Ontario, Canada."},{"issue":"1","key":"10.1016\/j.clbc.2025.07.013_bib0026","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/SLA.0000000000004451","article-title":"Residential racial segregation and disparities in breast cancer presentation, treatment, and survival","volume":"273","author":"Poulson","year":"2021","journal-title":"Ann Surg"},{"issue":"5","key":"10.1016\/j.clbc.2025.07.013_bib0027","first-page":"334","article-title":"Racial and ethnic disparities in the receipt of cancer treatment","volume":"94","author":"Shavers","year":"2002","journal-title":"CancerSpectrum Knowledge Env"},{"issue":"2","key":"10.1016\/j.clbc.2025.07.013_bib0028","first-page":"18","article-title":"Challenges to using big data in health services research","volume":"87","author":"Kang","year":"2019","journal-title":"Univ West Ont Med J"},{"key":"10.1016\/j.clbc.2025.07.013_bib0029","series-title":"Ontario Marginalization Index: Frequently Asked Questions.ON: St. Michael\u2019s Hospital (Unity Health Toronto)","article-title":"(Unity Health Toronto) MG (Unity HT van IT (Public HO","author":"Matheson","year":"2023"}],"container-title":["Clinical Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820925002095?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820925002095?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T07:29:04Z","timestamp":1781076544000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1526820925002095"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S1526820925002095"],"URL":"https:\/\/doi.org\/10.1016\/j.clbc.2025.07.013","relation":{},"ISSN":["1526-8209"],"issn-type":[{"value":"1526-8209","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Appropriate Treatment for Stage 1 and 2 Her2-Positive and Triple-Negative Breast Cancer by Immigration Status in Ontario, Canada","name":"articletitle","label":"Article Title"},{"value":"Clinical Breast Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clbc.2025.07.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}